Management ChangeJun 22, 2026, 04:22 PM
Dyne Therapeutics Appoints Barry E. Greene as Independent Director
AI Summary
Dyne Therapeutics, Inc. announced the election of Barry E. Greene as a Class I director to its Board of Directors, effective June 22, 2026. Mr. Greene will serve until the 2027 Annual Meeting of Stockholders and has been determined to be an "independent" director. As part of his compensation, he received an option to purchase 57,463 shares of common stock at an exercise price of $20.87 per share, vesting over three years, and will receive annual cash compensation of $45,000.
Key Highlights
- Barry E. Greene elected as a Class I director to Dyne Therapeutics' Board.
- Mr. Greene will serve until the 2027 Annual Meeting of Stockholders.
- Board determined Mr. Greene is an "independent" director under Nasdaq rules.
- Received an option to purchase 57,463 shares of common stock.
- Option exercise price is $20.87 per share, vesting over three years.
- Will receive annual cash compensation of $45,000 as a Board member.
Price Impact
More from DYN